Home / Health / Leukemia Pills Match IV Treatment Success
Leukemia Pills Match IV Treatment Success
5 Jun
Summary
- Oral leukemia drug decitabine-cedazuridine plus venetoclax shows strong results.
- The two-pill combo is approved for older adults with acute myeloid leukemia.
- This treatment aims to reduce patient burden without sacrificing outcomes.
An oral medication combination, decitabine-cedazuridine and venetoclax, has demonstrated efficacy comparable to intravenous (IV) therapies for acute myeloid leukemia (AML). This breakthrough offers a less burdensome treatment option for older adults.
Researchers reported that the two-pill regimen showed strong response rates and survival outcomes in a recent clinical trial. The U.S. Food and Drug Administration (FDA) approved this oral combination in May for adults aged 75 and older, or patients who cannot tolerate conventional chemotherapy.
This all-oral therapy is expected to become a new standard of care, reducing the need for frequent hospital visits associated with traditional IV treatments. Patients are reportedly enthusiastic about avoiding monthly infusions, potentially improving their quality of life during treatment.
While not a cure, the ongoing treatment helps patients remain in remission. Researchers are exploring "triplet therapies" to further reduce leukemic cell levels with the ultimate goal of achieving a cure for AML patients.
